Home > Publications database > A genetic risk score to personalize prostate cancer screening, applied to population data. > print

001     156801
005     20240229123116.0
024 7 _ |a 10.1158/1055-9965.EPI-19-1527
|2 doi
024 7 _ |a pmid:32581112
|2 pmid
024 7 _ |a 1055-9965
|2 ISSN
024 7 _ |a 1538-7755
|2 ISSN
024 7 _ |a altmetric:84630455
|2 altmetric
037 _ _ |a DKFZ-2020-01118
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Huynh-Le, Minh-Phuong
|0 0000-0002-5025-4709
|b 0
245 _ _ |a A genetic risk score to personalize prostate cancer screening, applied to population data.
260 _ _ |a Philadelphia, Pa.
|c 2020
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1600331389_28430
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Sep;29(9):1731-1738
520 _ _ |a A polygenic hazard score (PHS)-the weighted sum of 54 SNP genotypes-was previously validated for association with clinically significant prostate cancer and for improved prostate cancer screening accuracy. Here, we assess the potential impact of PHS-informed screening.UK population incidence data (Cancer Research UK) and data from the Cluster Randomized Trial of PSA Testing for Prostate Cancer were combined to estimate age-specific clinically significant prostate cancer incidence (Gleason≥7, stage T3-T4, PSA ≥10, or nodal/distant metastases). Using hazard ratios estimated from the ProtecT prostate cancer trial, age-specific incidence rates were calculated for various PHS risk percentiles. Risk-equivalent age-when someone with a given PHS percentile has prostate cancer risk equivalent to an average 50-year-old man (50-years-standard risk)-was derived from PHS and incidence data. Positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was calculated using PHS-adjusted age groups.The expected age at diagnosis of clinically significant prostate cancer differs by 19 years between the 1st and 99th PHS percentiles: men with PHS in the 1st and 99th percentiles reach the 50-years-standard risk level at ages 60 and 41, respectively. PPV of PSA was higher for men with higher PHS-adjusted age.PHS provides individualized estimates of risk-equivalent age for clinically significant prostate cancer. Screening initiation could be adjusted by a man's PHS.Personalized genetic risk assessments could inform prostate cancer screening decisions.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Fan, Chun Chieh
|b 1
700 1 _ |a Karunamuni, Roshan
|b 2
700 1 _ |a Walsh, Eleanor I
|0 0000-0001-7696-3661
|b 3
700 1 _ |a Turner, Emma L
|0 0000-0003-2575-387X
|b 4
700 1 _ |a Lane, J Athene
|0 0000-0003-4581-9346
|b 5
700 1 _ |a Martin, Richard M
|0 0000-0002-7992-7719
|b 6
700 1 _ |a Neal, David E
|0 0000-0002-6033-5086
|b 7
700 1 _ |a Donovan, Jenny L
|0 0000-0002-6488-5472
|b 8
700 1 _ |a Hamdy, Freddie C
|b 9
700 1 _ |a Parsons, J Kellogg Kellogg
|b 10
700 1 _ |a Eeles, Rosalind A
|0 0000-0002-3698-6241
|b 11
700 1 _ |a Easton, Douglas F
|b 12
700 1 _ |a Kote-Jarai, Zsofia
|b 13
700 1 _ |a Amin Al Olama, Ali
|0 0000-0002-7178-3431
|b 14
700 1 _ |a Benlloch Garcia, Sara
|b 15
700 1 _ |a Muir, Kenneth
|0 0000-0001-6429-988X
|b 16
700 1 _ |a Grönberg, Henrik
|0 0000-0002-1073-2753
|b 17
700 1 _ |a Wiklund, Fredrik
|0 0000-0002-4623-0544
|b 18
700 1 _ |a Aly, Markus
|b 19
700 1 _ |a Schleutker, Johanna
|0 0000-0002-1863-0305
|b 20
700 1 _ |a Sipeky, Csilla
|b 21
700 1 _ |a Tammela, Teuvo
|b 22
700 1 _ |a Nordestgaard, Børge Grønne
|b 23
700 1 _ |a Key, Timothy J
|0 0000-0003-2294-307X
|b 24
700 1 _ |a Travis, Ruth C
|0 0000-0002-9571-0763
|b 25
700 1 _ |a Pharoah, Paul D P
|0 0000-0001-8494-732X
|b 26
700 1 _ |a Pashayan, Nora
|0 0000-0003-0843-2468
|b 27
700 1 _ |a Khaw, Kay-Tee
|b 28
700 1 _ |a Thibodeau, Stephen N
|b 29
700 1 _ |a McDonnell, Shannon K
|b 30
700 1 _ |a Schaid, Daniel J
|b 31
700 1 _ |a Maier, Christiane
|b 32
700 1 _ |a Vogel, Walther
|b 33
700 1 _ |a Luedeke, Manuel
|b 34
700 1 _ |a Herkommer, Kathleen
|0 0000-0002-0339-3394
|b 35
700 1 _ |a Kibel, Adam S
|b 36
700 1 _ |a Cybulski, Cezary
|b 37
700 1 _ |a Wokolorczyk, Dominika
|b 38
700 1 _ |a Kluzniak, Wojciech
|b 39
700 1 _ |a Cannon-Albright, Lisa A
|0 0000-0003-2602-3668
|b 40
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 41
|u dkfz
700 1 _ |a Schöttker, Ben
|0 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
|b 42
|u dkfz
700 1 _ |a Holleczek, Bernd
|b 43
700 1 _ |a Park, Jong Y
|b 44
700 1 _ |a Sellers, Thomas A
|b 45
700 1 _ |a Lin, Hui-Yi
|0 0000-0002-3307-5549
|b 46
700 1 _ |a Slavov, Chavdar Kroumov
|b 47
700 1 _ |a Kaneva, Radka P
|b 48
700 1 _ |a Mitev, Vanio I
|b 49
700 1 _ |a Batra, Jyotsna
|b 50
700 1 _ |a Clements, Judith A
|b 51
700 1 _ |a Spurdle, Amanda B
|0 0000-0003-1337-7897
|b 52
700 1 _ |a Teixeira, Manuel R
|0 0000-0002-4896-5982
|b 53
700 1 _ |a Paulo, Paula
|b 54
700 1 _ |a Maia, Sofia
|b 55
700 1 _ |a Pandha, Hardev
|b 56
700 1 _ |a Michael, Agnieszka
|0 0000-0002-7262-6227
|b 57
700 1 _ |a Mills, Ian G
|0 0000-0001-5347-5083
|b 58
700 1 _ |a Andreassen, Ole A
|b 59
700 1 _ |a Dale, Anders M
|b 60
700 1 _ |a Seibert, Tyler M
|0 0000-0002-4089-7399
|b 61
773 _ _ |a 10.1158/1055-9965.EPI-19-1527
|g p. cebp.1527.2019 -
|0 PERI:(DE-600)2036781-8
|n 9
|p 1731-1738
|t Cancer epidemiology, biomarkers & prevention
|v 29
|y 2020
|x 1538-7755
909 C O |o oai:inrepo02.dkfz.de:156801
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 41
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 42
|6 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2020-01-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-17
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER EPIDEM BIOMAR : 2018
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-17
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER EPIDEM BIOMAR : 2018
|d 2020-01-17
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21